DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

Information source: Actavis Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ankle Sprain

Intervention: Diclofenac epolamine (Drug); Placebo (Other)

Phase: Phase 3

Status: Completed

Sponsored by: Actavis Inc.

Official(s) and/or principal investigator(s):
Henry Lau, PhD, Study Director, Affiliation: Actavis Inc.


To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain

Clinical Details

Official title: Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing the Safety and Efficacy of Generic Diclofenac Epolamine to Flector® Patch in the Treatment of Acute Pain Due to Minor Ankle Sprain

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Bioequivalence between test diclofenac epolamine patch and reference (Flector) patch in VAS score - changes from baseline

Secondary outcome: Superiority of test diclofenac epolamine patch over placebo and of reference (Flector) patch over placebo in VAS score - changes from baseline

Detailed description: To evaluate the therapeutic equivalence and safety of generic diclofenac epolamine 1. 3% patch (Watson Laboratories, Inc.) and Flector® (diclofenac epolamine 1. 3% patch) (Pfizer) in the treatment of acute pain due to minor ankle sprain. To demonstrate the superiority of the efficacy of the test and reference products over that of the vehicle control in the treatment of acute pain due to minor ankle sprain. To access application site reactions and patch adhesion between treatment groups.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: 1. Male or Non pregnant females, 18-65 years of age 2. Signed informed consent obtained that meets all criteria of current FDA and Health Insurance Portability and Accountability Act regulations 3. Subject has a diagnosis of uncomplicated acute minor ankle sprain: Grade I and II (as defined by the America Academy of Orthopedic Surgeons AAOS) 4. Ankle sprain must have occurred < 48 hours before study entry with baseline pain score of > 50 mm on a 100 mm Visual Analog Scale (VAS) upon active mobilization 5. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (on stable treatment for at least 3 months) NuvaRing® (vaginal contraceptive); Implanon™ (contraceptive implant) double barrier methods (e. g. condom and spermicide), intrauterine device, or abstinence with a 2nd acceptable method of birth control, should the patient become sexually active. A sterile sexual partner is NOT considered an adequate form of birth control. 6. All male subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug. Abstinence is an acceptable method of birth control. Female partners should use an acceptable method of birth control as described in Item Number 5. 7. Subject is free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 8. Subject shows willingness and capability to cooperate to the extent and degree required by the protocol. 9. Subject is willing to refrain from using any other pain medication during their participation. Exclusion Criteria: 1. Pregnant or breastfeeding female. 2. Sprain occurred > 48 hours prior to study enrollment. 3. Ankle sprain requires an orthopedic or surgical treatment. 4. Ankle sprain treated prior to study entry by topical, oral, or parenteral nonsteroidal antiinflammatory drug (NSAID), physiotherapy, ultrasound, physical therapy or acupuncture. 5. Baseline self-evaluation of pain on active mobilization by the VAS < 50 mm. 6. Non-intact or damaged skin within the area to be treated, e. g., eczema, psoriasis, exudative, dermatitis, infected lesion, burn or wound. 7. Medical history of asthma, urticaria, angioedema, bronchospasm, ulcer disease, gastrointestinal bleeding, hypertension, edema, heart failure or cardiovascular disease. 8. Medical history of any chronic pain disorder. 9. Coagulation defects. 10. Severe cardiac, renal or hepatic impairment. 11. Severe systemic disease (e. g., cancer, severe acute infection). 12. Use within one month prior to randomization of 1.) immunomodulators or immunosuppressive therapies, 2.) interferon, 3.) oral or parenteral corticosteroids or 4.) cytotoxic drugs. 13. Use within 7 days prior to randomization of any topical agents on the affected ankle. 14. Use within 7 days prior to randomization of topical, oral or parenteral treatment with NSAIDs or aspirin. 15. Use within 12 hours prior to randomization of an analgesic. Eg. Acetaminophen (Tylenol®). 16. Known allergy or hypersensitivity to diclofenac, aspirin or other NSAIDs, or any excipient in the test product or brand product (Flector). 17. History of uncontrolled chronic or acute concomitant disease which, in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results.

Locations and Contacts

Site 21, Birmingham, Alabama 35209, United States

Site 24, Goodyear, Arizona 85395, United States

Site 08, Carlsbad, California 92008, United States

Site 05, Ventura, California 93003, United States

Site 16, Clinton, Connecticut 84105, United States

Site 03, Riverton, Connecticut 84065, United States

Site 11, Daytona, Florida 32117, United States

Site 09, DeLand, Florida 32720, United States

Site 07, Miami, Florida 33155, United States

Site 13, Miami, Florida 33155, United States

Site 14, Miami, Florida 33144, United States

Site 02, West Palm Beach, Florida 33409, United States

Site 26, Lexington, Kentucky 40509, United States

Site 12, Gretna, Louisiana 70056, United States

Site 23, Kalamazoo, Michigan 85395, United States

Site 41, Traverse City, Michigan 49684, United States

Site 10, Omaha, Nebraska 32117, United States

Site 29, Berlin, New Jersey 08009, United States

Site 18, Brooklyn, New York 11201, United States

Site 19, Cincinnati, Ohio 45246, United States

Site 30, Columbus, Ohio 43214, United States

Site 35, Oklahoma City, Oklahoma 73112, United States

Site 37, Downingtown, Pennsylvania 19355, United States

Site 27, State College, Pennsylvania 16801, United States

Site 15, Austin, Texas 78756, United States

04, El Paso, Texas 93003, United States

Site 34, Houston, Texas 77089, United States

Site 36, Lake Jackson, Texas 77566, United States

Site 22, San Antonio, Texas 78218, United States

Site 31, Danville, Virginia 24541, United States

Site 06, Newport News, Virginia 23606, United States

Additional Information

Starting date: May 2014
Last updated: December 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017